PrEP in Italy

The time may be ripe but who’s paying the bill? A nationwide survey on physicians’ attitudes towards using antiretrovirals to prevent HIV infection

Antonio Di Biagio, Niccolò Riccardi, Alessio Signori, Renato Maserati, Silvia Nozza, Andrea Gori, Stefano Bonora, Marco Borderi, Diego Ripamonti, Maria Cristina Rossi, Giancarlo Orofino, Tiziana Quirino, Giuseppe Nunnari, Benedetto Maurizio Celesia, Salvatore Martini, Caterina Sagnelli, Giovanni Mazzola, Pietro Colletti, Dario Bartolozzi, Teresa Bini & 4 others Nicoletta Ladisa, Filippo Castelnuovo, Annalisa Saracino, Sergio Lo Caputo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Several studies have demonstrated the efficacy of the oral pre-exposure prophylaxis (PrEP) with tenofovir (with or without emtricitabine) on preventing HIV-negative partners of HIV infected patients to become infected through sexual contacts. PrEP is already available in the United States and now is approved by European Medicine Agency. In this setting we would like to gauge physicians’ knowledge, acquaintance with and attitude to include PrEP in their clinical practice. A cross sectional survey was conducted among Italian physicians expert on antiretroviral therapy. Out of 146 physicians, 35% of participants declared to be familiar with PrEP but only 46% of them believed that, currently, there are not enough reasons to make it available in Italy. 51% of physicians have already been attracted to prescribe it and 63.4% have been openly asked about PrEP. The main concerns noticed were: the risk of acquire other sexual transmitted diseases (STDs) (70% of physicians feared that PrEP could favor STDs spread), the potential harmful of PrEP if not adequately implemented and, especially the risk of possible side effects if not properly used. Nevertheless, 55.9% of participants believed that Health Authorities face an ethical obligation to make PrEP available as part of the strategies to protect from HIV transmission and half of the respondents asked for further researches to better define the role for PrEP. Attitudes regarding PrEP impact on Italian National Health Organization were also very interesting: 57.5% of participants did not believe that investing in PrEP would be an appropriate use of healthcare resources, while 70.6% affirmed that PrEP’s financial coverage should not be funded by the Italian National System of Health (SSN). This survey showed a high awareness of PrEP potential among Italian physicians coupled with a great deal of skepticism about how and if implementing it in clinical practice.

Original languageEnglish
Article numbere0181433
JournalPLoS One
Volume12
Issue number7
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

national surveys
HIV infections
physicians
Italy
HIV Infections
disease control
Tenofovir
Health
Physicians
Gages
Medicine
HIV
Pre-Exposure Prophylaxis
Surveys and Questionnaires
gauges
cross-sectional studies
health services
mouth
medicine
Cross-Sectional Studies

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

PrEP in Italy : The time may be ripe but who’s paying the bill? A nationwide survey on physicians’ attitudes towards using antiretrovirals to prevent HIV infection. / Di Biagio, Antonio; Riccardi, Niccolò; Signori, Alessio; Maserati, Renato; Nozza, Silvia; Gori, Andrea; Bonora, Stefano; Borderi, Marco; Ripamonti, Diego; Rossi, Maria Cristina; Orofino, Giancarlo; Quirino, Tiziana; Nunnari, Giuseppe; Celesia, Benedetto Maurizio; Martini, Salvatore; Sagnelli, Caterina; Mazzola, Giovanni; Colletti, Pietro; Bartolozzi, Dario; Bini, Teresa; Ladisa, Nicoletta; Castelnuovo, Filippo; Saracino, Annalisa; Lo Caputo, Sergio.

In: PLoS One, Vol. 12, No. 7, e0181433, 01.07.2017.

Research output: Contribution to journalArticle

Di Biagio, A, Riccardi, N, Signori, A, Maserati, R, Nozza, S, Gori, A, Bonora, S, Borderi, M, Ripamonti, D, Rossi, MC, Orofino, G, Quirino, T, Nunnari, G, Celesia, BM, Martini, S, Sagnelli, C, Mazzola, G, Colletti, P, Bartolozzi, D, Bini, T, Ladisa, N, Castelnuovo, F, Saracino, A & Lo Caputo, S 2017, 'PrEP in Italy: The time may be ripe but who’s paying the bill? A nationwide survey on physicians’ attitudes towards using antiretrovirals to prevent HIV infection', PLoS One, vol. 12, no. 7, e0181433. https://doi.org/10.1371/journal.pone.0181433
Di Biagio, Antonio ; Riccardi, Niccolò ; Signori, Alessio ; Maserati, Renato ; Nozza, Silvia ; Gori, Andrea ; Bonora, Stefano ; Borderi, Marco ; Ripamonti, Diego ; Rossi, Maria Cristina ; Orofino, Giancarlo ; Quirino, Tiziana ; Nunnari, Giuseppe ; Celesia, Benedetto Maurizio ; Martini, Salvatore ; Sagnelli, Caterina ; Mazzola, Giovanni ; Colletti, Pietro ; Bartolozzi, Dario ; Bini, Teresa ; Ladisa, Nicoletta ; Castelnuovo, Filippo ; Saracino, Annalisa ; Lo Caputo, Sergio. / PrEP in Italy : The time may be ripe but who’s paying the bill? A nationwide survey on physicians’ attitudes towards using antiretrovirals to prevent HIV infection. In: PLoS One. 2017 ; Vol. 12, No. 7.
@article{014eac8f1f334bfbadfdd0a428314195,
title = "PrEP in Italy: The time may be ripe but who’s paying the bill? A nationwide survey on physicians’ attitudes towards using antiretrovirals to prevent HIV infection",
abstract = "Several studies have demonstrated the efficacy of the oral pre-exposure prophylaxis (PrEP) with tenofovir (with or without emtricitabine) on preventing HIV-negative partners of HIV infected patients to become infected through sexual contacts. PrEP is already available in the United States and now is approved by European Medicine Agency. In this setting we would like to gauge physicians’ knowledge, acquaintance with and attitude to include PrEP in their clinical practice. A cross sectional survey was conducted among Italian physicians expert on antiretroviral therapy. Out of 146 physicians, 35{\%} of participants declared to be familiar with PrEP but only 46{\%} of them believed that, currently, there are not enough reasons to make it available in Italy. 51{\%} of physicians have already been attracted to prescribe it and 63.4{\%} have been openly asked about PrEP. The main concerns noticed were: the risk of acquire other sexual transmitted diseases (STDs) (70{\%} of physicians feared that PrEP could favor STDs spread), the potential harmful of PrEP if not adequately implemented and, especially the risk of possible side effects if not properly used. Nevertheless, 55.9{\%} of participants believed that Health Authorities face an ethical obligation to make PrEP available as part of the strategies to protect from HIV transmission and half of the respondents asked for further researches to better define the role for PrEP. Attitudes regarding PrEP impact on Italian National Health Organization were also very interesting: 57.5{\%} of participants did not believe that investing in PrEP would be an appropriate use of healthcare resources, while 70.6{\%} affirmed that PrEP’s financial coverage should not be funded by the Italian National System of Health (SSN). This survey showed a high awareness of PrEP potential among Italian physicians coupled with a great deal of skepticism about how and if implementing it in clinical practice.",
author = "{Di Biagio}, Antonio and Niccol{\`o} Riccardi and Alessio Signori and Renato Maserati and Silvia Nozza and Andrea Gori and Stefano Bonora and Marco Borderi and Diego Ripamonti and Rossi, {Maria Cristina} and Giancarlo Orofino and Tiziana Quirino and Giuseppe Nunnari and Celesia, {Benedetto Maurizio} and Salvatore Martini and Caterina Sagnelli and Giovanni Mazzola and Pietro Colletti and Dario Bartolozzi and Teresa Bini and Nicoletta Ladisa and Filippo Castelnuovo and Annalisa Saracino and {Lo Caputo}, Sergio",
year = "2017",
month = "7",
day = "1",
doi = "10.1371/journal.pone.0181433",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - PrEP in Italy

T2 - The time may be ripe but who’s paying the bill? A nationwide survey on physicians’ attitudes towards using antiretrovirals to prevent HIV infection

AU - Di Biagio, Antonio

AU - Riccardi, Niccolò

AU - Signori, Alessio

AU - Maserati, Renato

AU - Nozza, Silvia

AU - Gori, Andrea

AU - Bonora, Stefano

AU - Borderi, Marco

AU - Ripamonti, Diego

AU - Rossi, Maria Cristina

AU - Orofino, Giancarlo

AU - Quirino, Tiziana

AU - Nunnari, Giuseppe

AU - Celesia, Benedetto Maurizio

AU - Martini, Salvatore

AU - Sagnelli, Caterina

AU - Mazzola, Giovanni

AU - Colletti, Pietro

AU - Bartolozzi, Dario

AU - Bini, Teresa

AU - Ladisa, Nicoletta

AU - Castelnuovo, Filippo

AU - Saracino, Annalisa

AU - Lo Caputo, Sergio

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Several studies have demonstrated the efficacy of the oral pre-exposure prophylaxis (PrEP) with tenofovir (with or without emtricitabine) on preventing HIV-negative partners of HIV infected patients to become infected through sexual contacts. PrEP is already available in the United States and now is approved by European Medicine Agency. In this setting we would like to gauge physicians’ knowledge, acquaintance with and attitude to include PrEP in their clinical practice. A cross sectional survey was conducted among Italian physicians expert on antiretroviral therapy. Out of 146 physicians, 35% of participants declared to be familiar with PrEP but only 46% of them believed that, currently, there are not enough reasons to make it available in Italy. 51% of physicians have already been attracted to prescribe it and 63.4% have been openly asked about PrEP. The main concerns noticed were: the risk of acquire other sexual transmitted diseases (STDs) (70% of physicians feared that PrEP could favor STDs spread), the potential harmful of PrEP if not adequately implemented and, especially the risk of possible side effects if not properly used. Nevertheless, 55.9% of participants believed that Health Authorities face an ethical obligation to make PrEP available as part of the strategies to protect from HIV transmission and half of the respondents asked for further researches to better define the role for PrEP. Attitudes regarding PrEP impact on Italian National Health Organization were also very interesting: 57.5% of participants did not believe that investing in PrEP would be an appropriate use of healthcare resources, while 70.6% affirmed that PrEP’s financial coverage should not be funded by the Italian National System of Health (SSN). This survey showed a high awareness of PrEP potential among Italian physicians coupled with a great deal of skepticism about how and if implementing it in clinical practice.

AB - Several studies have demonstrated the efficacy of the oral pre-exposure prophylaxis (PrEP) with tenofovir (with or without emtricitabine) on preventing HIV-negative partners of HIV infected patients to become infected through sexual contacts. PrEP is already available in the United States and now is approved by European Medicine Agency. In this setting we would like to gauge physicians’ knowledge, acquaintance with and attitude to include PrEP in their clinical practice. A cross sectional survey was conducted among Italian physicians expert on antiretroviral therapy. Out of 146 physicians, 35% of participants declared to be familiar with PrEP but only 46% of them believed that, currently, there are not enough reasons to make it available in Italy. 51% of physicians have already been attracted to prescribe it and 63.4% have been openly asked about PrEP. The main concerns noticed were: the risk of acquire other sexual transmitted diseases (STDs) (70% of physicians feared that PrEP could favor STDs spread), the potential harmful of PrEP if not adequately implemented and, especially the risk of possible side effects if not properly used. Nevertheless, 55.9% of participants believed that Health Authorities face an ethical obligation to make PrEP available as part of the strategies to protect from HIV transmission and half of the respondents asked for further researches to better define the role for PrEP. Attitudes regarding PrEP impact on Italian National Health Organization were also very interesting: 57.5% of participants did not believe that investing in PrEP would be an appropriate use of healthcare resources, while 70.6% affirmed that PrEP’s financial coverage should not be funded by the Italian National System of Health (SSN). This survey showed a high awareness of PrEP potential among Italian physicians coupled with a great deal of skepticism about how and if implementing it in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85026238824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026238824&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0181433

DO - 10.1371/journal.pone.0181433

M3 - Article

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e0181433

ER -